Basic fibroblast growth factor

• US 5,155,214 A
• Filed: 01/08/1990
• Issued: 10/13/1992
• Est. Priority Date: 03/05/1984
• Status: Expired due to Term

• Current Assignee: Salk Institute for Biological Studies
• Original Assignee: Salk Institute for Biological Studies
• Inventors: Bohlen, Peter, Gospodarowicz, Denis, Ling, Nicholas C., Baird, Andrew J., Esch, Frederick S.
• Primary Examiner(s): Lacey, David L.
• Assistant Examiner(s): Guest, Shelly
• Application Number:
  US07/462,126
• Time in Patent Office: 1,009 Days
• Field of Search: 530/399, 514/12, 435/69.4
• US Class Current: 530/399
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/503 basic FGF [bFGF]

Abstract

Substantially pure mammalian basic fibroblast growth factors are produced. The amino acid residue sequences of bovine and human bFGF are disclosed as well as a DNA chain encoding the polypeptide of the bovine species. By appropriately inserting a synthesized DNA chain into a cloning vector and using the cloning vector to transform cells, synthetic bFGF can be obtained from transformed cell lines, both prokaryotic and eukaryotic.

Claims

1. Substantially pure mammalian basic fibroblast growth factor (FGF) containing the amino acid sequence:

##STR4## or a naturally occurring homologous sequence of another mammalian species, which growth factor is effective to stimulate proliferation of endothelial cells in vitro.

2. Mammalian basic FGF according to claim 1 which is produced recombinantly.

3. A composition for wound healing, which composition comprises an amount of mammalian basic FGF effective to promote therapeutic healing of a wound in a mammal, which basic FGF according to claim 1 is dispersed in a pharmaceutically acceptable liquid or solid carrier.